Initially, we found that membrane expression of B7-H3 was present in 91.8% of the osteosarcoma lesions, and the intensity of B7-H3 expression in osteosarcoma was significantly correlated with tumor progression, immune cells infiltration and overall survival status, suggesting that B7-H3 could be as a potential predictor and therapeutic target in OS patients [23]. Here, CD276 is linked to osteosarcoma.